11 found
Order:
  1.  19
    Big Data and Ethics Review for Health Systems Research in LMICs: Understanding Risk, Uncertainty and Ignorance—And Catching the Black Swans?Türkay Dereli, Yavuz Coşkun, Eugene Kolker, Öner Güner, Mehmet Ağırbaşlı & Vural Özdemir - 2014 - American Journal of Bioethics 14 (2):48-50.
  2.  22
    One Size Does Not Fit All: Toward “Upstream Ethics”?Vural Ozdemir & Bartha Maria Knoppers - 2010 - American Journal of Bioethics 10 (6):42-44.
  3.  24
    Selling Translational Research: Is Science a Value-Neutral Autonomous Enterprise?Zubin Master & Vural Özdemir - 2008 - American Journal of Bioethics 8 (3):52-54.
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  4.  65
    Challenges for Corporate Ethics in Marketing Genetic Tests.Bryn Williams-Jones & Vural Ozdemir - 2008 - Journal of Business Ethics 77 (1):33 - 44.
    Public discussions of ethical issues related to the biotechnology industry tend to treat “biotechnology” as a single, undifferentiated technology. Similarly, the pros and cons associated with this entire sector tend to get lumped together, such that individuals and groups often situate themselves as either “pro-” or “anti-” biotechnology as a whole. But different biotechnologies and their particular application context pose very different challenges for ethical corporate decision-making. Even within a single product category, different specialty products can pose strikingly different ethical (...)
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  5. Full Throttle: COVID-19 Open Science to Build Planetary Public Goods.Rene Von Schomberg & Vural Ozdemir - 2020 - Omics: A Journal of Integrative Biology 24:1-3.
    this article makes the case that the rationale of open science and responsible innovation will help to build public planetary goods: the necessity of this rationale is illustrated on the COViD-19 case.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  6.  12
    Challenges for Corporate Ethics in Marketing Genetic Tests.Bryn Williams-Jones & Vural Ozdemir - 2008 - Journal of Business Ethics 77 (1):33-44.
    Public discussions of ethical issues related to the biotechnology industry tend to treat "biotechnology" as a single, undifferentiated technology. Similarly, the pros and cons associated with this entire sector tend to get lumped together, such that individuals and groups often situate themselves as either "pro-" or "anti-" biotechnology as a whole. But different biotechnologies and their particular application context pose very different challenges for ethical corporate decision-making. Even within a single product category, different specialty products can pose strikingly different ethical (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  7.  13
    What To Do When the Risk Environment Is Rapidly Shifting and Heterogeneous? Anticipatory Governance and Real-Time Assessment of Social Risks in Multiply Marginalized Populations Can Prevent IRB Mission Creep, Ethical Inflation or Underestimation of Risks.Vural Ozdemir - 2009 - American Journal of Bioethics 9 (11):65-68.
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  8.  15
    Glocal Bioethics: When International IRB Collaboration Confronts Local Politics.Edward S. Dove & Vural Özdemir - 2014 - American Journal of Bioethics 14 (5):20-23.
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  9.  29
    ACCE, Pharmacogenomics, and Stopping Clinical Trials: Time to Extend the CONSORT Statement?Bartha M. Knoppers, Yann Joly & Vural Ozdemir - 2011 - American Journal of Bioethics 11 (3):11-13.
    (2011). ACCE, Pharmacogenomics, and Stopping Clinical Trials: Time to Extend the CONSORT Statement? The American Journal of Bioethics: Vol. 11, No. 3, pp. 11-13.
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  10.  18
    Are We Asking the Right Ethics Questions on Drug Shortages? Suggestions for a Global and Anticipatory Ethics Framework.Vural Ozdemir, Yann Joly, Edward S. Dove, Aspasia Karalis, Denise Avard & Bartha M. Knoppers - 2012 - American Journal of Bioethics 12 (1):13 - 15.
    The American Journal of Bioethics, Volume 12, Issue 1, Page 13-15, January 2012.
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark  
  11.  10
    A Code of Ethics for Ethicists: What Would Pierre Bourdieu Say? “Do Not Misuse Social Capital in the Age of Consortia Ethics”.Vural Özdemir, Hakan Kılıç, Arif Yıldırım, Effy Vayena, Edward S. Dove, Kıvanç Güngör, Adrian LLerena & Semra Şardaş - 2015 - American Journal of Bioethics 15 (5):64-67.